Protocol Completion For Tropine 3 Clinical Trial Ensures Rally In Pristine Solutions (PRTN)

Following the news of an agreement with Rox San Pharmacy and completion of Protocol for the Clinical Trial for Tropine 3, the shares of Pristine Solutions (OTC: PRTN) continued the upward journey with a 76% gain from an intra-day low of $0.17 on September 4, 2012. Pristine Solutions came into the lime light nearly two […]

Three-Dimensional Bioprinter’s Potential Revives Interest In Organovo Holdings (ONVO)

The developer of the NovoGen MMX Bioprinter, Organovo Holdings (OTC: ONVO), continued to attract traders following an “outperform” rating a week ago from Zacks Small Cap Research. In yesterday’s trading session, the share price rose by $0.07 to $2.23 in the first hour of trading and resisted short sellers for the rest of the day. […]